PF-Atlas › Clinical Trials › NCT02688647
A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
Belumosudil · Phase 2
Registry ID
NCT02688647
Phase
Phase 2
Status
Completed
Drug / intervention
Belumosudil
Sponsor
Kadmon Corporation, LLC
Start
2016-05-26
Enrollment
76
Locations
10
About this trial
This Phase 2 study is to be conducted to evaluate the safety, tolerability, and activity of 400 mg of belumosudil orally (PO) once-daily (QD) compared to Best Supportive Care (BSC) in male and postmenopausal/surgically sterilized female subjects with Idiopathic Pulmonary Fibrosis (IPF). The primary objectives are to evaluate the: * Change in Forced Vital Capacity (FVC) from baseline to 24 weeks after dosing with belumosudil 400 mg PO QD in subjects with IPF compared to BSC * Safety and tolerability of belumosudil 400 mg PO QD when administered for 24 weeks to subjects with IPF compared to BSC
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02688647 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.